Original Broadcast Date: Wednesday, September 14, 2016. Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-16-312-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.
Staphylococcus Aureus bacteremia can be difficult to treat and can carry a significant morbidity and mortality risk. This activity will discuss best practices and compare different treatments for Staphylococcus aureus bacteremia. Discussion regarding the role of appropriate vancomycin concentrations in treatment of bacteremia will also be addressed. The impact of consultations and standards of care will be reviewed.
This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.
At the conclusion of this activity, participants should be able to:
- Review current best practices for the management of Staphylococcus aureus bacteremia
- Compare and contrast alternative therapies for Staphylococcus bacteremia
- Discuss clinical data related to "elevated" vancomycin minimum inhibitory concentrations
- Demonstrate the impact of routine infectious diseases consultation on compliance with standards of care
Alan Gross, PharmD, BCPS-AQ ID
Infectious Diseases Pharmacist
Univ. of Illinois Hospital and Health Sciences System
Clinical Assistant Professor
University of Illinois at Chicago, College of Pharmacy
Kathryn E. DeSear, PharmD, BCPS, AAHIVP
Manager, Antimicrobial Stewardship
Community Health Systems
No commercial funding was received for this activity.
Release Date: 9-14-2016
Expiration Date: 9-14-2019
This CE activity is jointly provided by ProCE, Inc. and SIDP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-16-312-H01-P has been assigned to this knowledge-based home-study CE activity (initial release date 9-14-16). This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Successful completion of the online post-test and evaluation at www.ProCE.com is required to receive CE credit. CE credit will be uploaded to NABP/CPE Monitor. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. Gross has served as a Consultant for Actavis. Dr. DeSear has no relevant commercial and/or financial relationships to disclose.
Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
|Activity Number||Credit Amount||Accreditation Period|
|0221-9999-16-312-H01-P||1 Contact Hour||September 14, 2016 - September 14, 2019|